A Phase 3b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of an Adjuvanted Chikungunya Virus Virus-like Particle (CHIKV VLP) Vaccine for the Prevention of Chikungunya Disease in Adolescents (12 to <18 Years) and Adults (≥18 Years)

Study EBSI-CV-317-007 is a field study to evaluate the efficacy, immunogenicity, and safety of CHIKV VLP vaccine. The study was designed using infectious disease models and advanced analytics to guide region and clinical site prioritization, define the timing of study activities, and optimize the study parameters to local epidemiological conditions for CHIKV disease to overcome the challenges of assessing efficacy for CHIKV VLP vaccine.

开始日期2026-05-26

申办/合作机构

Bavarian Nordic A/S

[+4]

NCT07003984

/ Active, not recruiting临床3期

A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children 1 to <12 Years of Age

The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 1 to <12 years of age.

开始日期2025-06-05

申办/合作机构

Bavarian Nordic A/S

NCT06928753

/ Recruiting临床4期IIT

Real-world Effectiveness, Safety, and Immunogenicity of Chikungunya Vaccination During an Epidemic Period: an Ambispective Study in Réunion Island and French Guiana.

In the context of the ongoing chikungunya epidemic in Réunion Island and the anticipated epidemic in French Guiana, the investigators propose an ambispective study to evaluate the real-world effectiveness, safety, and immunogenicity of the recommended vaccines, IXCHIQ® and VIMKUNYA®, as defined by the French National Authority for Health (HAS).

开始日期2025-04-18

申办/合作机构-

100 项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的临床结果

登录后查看更多信息

100 项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的转化医学

登录后查看更多信息

100 项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的专利（医药）

登录后查看更多信息

105

项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的文献（医药）

2027-01-01·Methods in molecular biology (Clifton, N.J.)

In Silico Drug Design of Chikungunya Antivirals: Using Consensus Methods for Virtual Screening

Article

作者: Battini, Leandro

Structure-based virtual screening is an attractive strategy in drug design. It enables the selection of potential binders to target biomolecules with known molecular structures, providing a rational framework for studying their mechanisms of action and guiding further optimization. However, accurately predicting the free energy of binding remains an extremely challenging task, and the available tools only provide approximate estimates. In this context, one strategy to improve the predictive power of virtual screening and increase the probability of identifying true binders is to employ multiple docking algorithms and combine their results using a consensus method. In this chapter, we will describe a step-by-step methodology to perform this task. We will conduct a virtual screening using AutoDock Vina, AutoDock4, and LeDock, and then combine their results employing the Exponential Consensus Ranking algorithm. Finally, we will discuss possible extensions of this strategy, such as incorporating Molecular Dynamics simulations as an additional filter in the virtual screening or integrating the novel Artificial Intelligence-based methodologies into the consensus framework.

2027-01-01·Methods in molecular biology (Clifton, N.J.)

Overview of Chikungunya Virus Epidemiology, Biology, and Pathogenesis

Review

作者: Filomatori, Claudia ; Castro, Eliana F

Chikungunya virus (CHIKV), an arthropod-borne alphavirus within the Togaviridae family, is transmitted primarily by Aedes aegypti and Aedes albopictus. The virus causes an acute febrile illness characterized by severe, often bilateral polyarthralgia, with potential progression to chronic musculoskeletal pain and rare systemic complications involving cardiovascular and neurological systems. CHIKV exhibits a spherical, enveloped virion (~70 nm) with T = 4 icosahedral symmetry, incorporating E1/E2 glycoprotein heterodimers that mediate receptor binding and membrane fusion. Its positive-sense RNA genome (~11.8 kb) encodes nonstructural proteins for replication and structural proteins for virion assembly. Replication occurs in cytoplasmic spherules, involving synthesis of genomic and subgenomic RNAs, followed by glycoprotein maturation and budding at the plasma membrane. Epidemiologically, CHIKV has expanded beyond Africa and Asia, with major outbreaks driven by adaptive mutations enhancing transmission via A. albopictus. Since introduction to the Americas in 2013, the global incidence remains high, with >180,000 confirmed cases reported in 2025. Preventive strategies rely on vector control and vaccination; VLP-based vaccines (e.g., Vimkunya) show promise, while live-attenuated formulations face safety concerns. No licensed antivirals exist; current management is supportive, though investigational therapies targeting viral replication and immune modulation are under development.

2026-04-01·LANCET INFECTIOUS DISEASES

Chikungunya adolescent vaccination and the distinct risk–benefit landscapes

Article

作者: Barratt-Boyes, Simon ; Marques, Ernesto T A

109

项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的新闻（医药）

2026-08-21

·BioSpace

Bavarian Nordic Reports Strong First Half 2026 Results

COPENHAGEN, Denmark, August 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the second quarter and first half of 2026 and released its financial calendar for 2027. Financial highlights Revenue in the second quarter (Q2) increased by 23% to DKK 2,034 million. Travel Health revenue increased by 45% (56% when adjusting for discontinued partnerships) to DKK 1,022 million, primarily driven by continued strong RabAvert/Rabipur sales (DKK 649 million, +55%), as well as strong Encepur sales (DKK 268 million, +58%) and the continued launch of Vimkunya (DKK 37 million, +415%). Public Preparedness revenue increased by 6% to DKK 975 million driven by a stronger-than-expected contract base in 2026, while also reflecting the normal quarterly phasing of revenue from this business. EBITDA in the second quarter (Q2) was DKK 925 million, corresponding to an EBITDA margin of 45%. Gross margin reached 61% driven by an advantageous product mix and strong manufacturing performance. First half (H1) total revenue was DKK 3,092 million, an increase of 3%, reflecting the strong growth in Travel Health, offset by lower Public Preparedness revenue in line with expectations (no material impact from mpox outbreaks expected in 2026). EBITDA in the first half was DKK 1,090 million, corresponding to an EBITDA margin of 35%. Updated full-year guidance The Company has upgraded its full-year guidance for 2026 and now expects revenue of approximately DKK 5,700 million, corresponding to the upper end of the previous guidance range (DKK 5,500 – 5,700 million). The EBITDA margin is now expected to reach approximately 30% (previously approximately 28%). Share buy-back The planned share buy-back program of DKK 500 million was completed in July. The company will initiate another share buy-back program in 2026 of up to DKK 750 million, reflecting the strength of the Company’s balance sheet and cash generation while preserving the ability to pursue value-accretive acquisition opportunities. DKK million Q2 2026 Q2 2025 H1 2026 H1 2025 2026 Guidance Revenue 2,034 1,652 3,092 2,998 ~5,700 EBITDA margin 45% 33% 35% 32% ~30% Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “We delivered a strong first half of 2026, with record Travel Health revenue, continued robust profitability and solid execution across our manufacturing network. Demand for our rabies vaccines remained exceptionally strong across key markets, while our chikungunya vaccine continued to gain traction in Europe following multiple launches during the period. In Public Preparedness, additional government contracts for our mpox/smallpox vaccine strengthened our revenue base and enhanced visibility beyond 2026, while further regulatory progress broadened the potential use of the vaccine across wider populations. Based on our first-half performance, operational momentum and the business secured for the remainder of the year, we remain confident in delivering our upgraded financial guidance for 2026.” Business highlights for the second quarter Additional regulatory approvals were obtained for the Vimkunya chikungunya vaccine in Switzerland and Canada, and Bavarian Nordic’s partner, Eurofarma, submitted a marketing authorization application to the Brazilian Health Regulatory Agency (Anvisa) for the vaccine. Vimkunya was launched in the Netherlands, Belgium and Switzerland, and is now available in the US and 14 European countries. Additional launches are planned for the second half of 2026. Regulatory advancements were also made for the mpox and smallpox vaccine as the European Commission in August approved the use of MVA-BN for children 2 to less than 12 years of age following a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency in June. The Public Preparedness business was strengthened as the US Government exercised additional options valued at USD 97 million under the existing contract to supply a freeze-dried formulation of JYNNEOS ® smallpox vaccine. Furthermore, another contract valued over DKK 700 million with an undisclosed government was received for delivery in 2026 and 2027. Financial calendar 2027 The dates for the annual and quarterly reports and the annual general meeting in 2027 have been determined as follows: Annual Report 2026 March 11, 2027 Annual General Meeting April 13, 2027 1 First quarter report (Q1) May 14, 2027 Half-year report (H1) August 25, 2027 Nine-month report (Q3) November 10, 2027 1 Pursuant to Article 12 of the Articles of Association, shareholders who wish to submit a request for proposals for consideration at the annual general meeting must lodge this with the Company no later than Monday, March 1, 2027. Conference call and webcast The management of Bavarian Nordic will host an investor/analyst call today at 2 pm CEST (8 am EDT) to present the interim results followed by a Q&A session. A listen-only version of the call and presentation slides can be accessed via . To join the Q&A session, please register in advance via . About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors: Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com , Tel: +45 44 74 99 58 Graham Morrell, Gilmartin Group, graham@gilmartinir.com , Tel: +1 781 686 9600 Contact media: Isabel Hagbrink, Head of Media Relations, isha@bavarian-nordic.com , Tel: +45 71 79 67 33 Company Announcement no. 36 / 2026 Attachments Bavarian Nordic H1 2026 Report Bavarian Nordic Reports Strong First Half 2026 Results

上市批准疫苗财报加速审批

2026-07-15

·BioSpace

Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil

COPENHAGEN, Denmark, July 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that its partner, Eurofarma, has submitted a marketing authorization application to the Brazilian Health Regulatory Agency (Anvisa) for Bavarian Nordic’s chikungunya vaccine, CHIKV VLP, for the prevention of disease caused by chikungunya virus in individuals 12 years of age and older. The submission represents a key milestone in the partnership established between Bavarian Nordic and Eurofarma and marks an important step toward making the vaccine available in one of the countries most affected by chikungunya. Brazil accounts for a substantial proportion of reported chikungunya cases and related deaths globally, underscoring the continued need for effective preventive measures against the disease. Paul Chaplin, President & CEO of Bavarian Nordic , said: “The submission to Anvisa represents an important milestone in our strategy to expand access to our chikungunya vaccine beyond traditional travel markets and into regions where the disease poses a significant and recurring public health burden. Through our partnership with Eurofarma, we are combining global vaccine innovation with strong local expertise to support access for populations living at risk of chikungunya. We look forward to working closely with Eurofarma and Anvisa throughout the review process.” João Siffert, Vice President of Innovation at Eurofarma , said: “The introduction of the vaccine reinforces Eurofarma’s commitment to expanding public access to innovative healthcare products capable of addressing important public health challenges with efficacy and safety. Chikungunya continues to spread in Brazil and generates a significant impact on patients, not only during the acute infection but also through chronic effects, affecting both patients and healthcare systems. This vaccine uses a modern and widely validated technology, with a favorable safety pro the ability to induce a rapid immune response, contributing to strengthening disease prevention efforts.” About the partnership with Eurofarma In January 2026, Bavarian Nordic entered into an exclusive distribution agreement with Eurofarma covering Brazil. Under the agreement, Eurofarma is responsible for regulatory activities, commercialization, and distribution of the vaccine in the territory, while Bavarian Nordic remains the manufacturer and supplier of the product. Eurofarma also holds a right of first refusal for future opportunities in the broader Latin American region. About CHIKV VLP CHIKV VLP is a single dose, prefilled, adjuvanted VLP recombinant protein vaccine for active immunization to prevent disease caused by chikungunya virus (CHIKV) in individuals 12 years and older. It is designed to induce a robust seroresponse, with protective immunity starting to develop as early as one week after vaccination. The vaccine does not contain viral genetic material and is therefore non-infectious and unable to cause disease, supporting its use across a broad population. The vaccine has already been approved by the U.S. Food and Drug Administration (FDA), the European Commission, the UK Medicines and Healthcare products Regulatory Agency (MHRA), Swissmedic and Health Canada under the trade name VIMKUNYA ® . About chikungunya Chikungunya is a mosquito-borne disease caused by the chikungunya virus. In the past 20 years, the virus has emerged across several regions in Asia, Africa, and the Americas, including many popular travel destinations, often causing large unpredictable outbreaks. Since its discovery, chikungunya has been identified in more than 110 countries 1 . Chikungunya typically presents with acute symptoms, including fever, rash, fatigue, headache, and often severe and incapacitating joint pain. Most patients recover, but 30-40% of those affected may develop chronic symptoms that can last for months or even years 2 . In 2025, more than 500,000 cases of chikungunya and nearly 200 associated deaths were reported worldwide 3 . More than half of the reported cases and associated deaths were reported from Brazil 4 . Recent data suggest that chikungunya is severely underreported and often misdiagnosed as dengue fever due to a similar symptom profile 5 . About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit . About Eurofarma Founded in 1972, Eurofarma covers key pharmaceutical segments and is the leader in medical prescriptions in Brazil. A Brazilian multinational company operating in 24 countries, with full coverage across Latin America and retail leadership in the region, the company also maintains operations in the United States and Africa, with more than 13,000 employees and 10 manufacturing facilities. In 2025, Eurofarma produced 630 million units. That same year, the company invested over USD 137 million in innovation projects and achieved net revenue exceeding USD 2.24 billion. For more information: . Contact investors: Europe: Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com , Tel. +45 33 26 83 83 US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com , Tel: +1 781 686 9600 Contact media: Nicole Seroff, Vice President Corporate Affairs, nise@bavarian-nordic.com , Tel: +45 53 88 06 03 1 World Health Organization (WHO). Chikungunya. 2 European Centre for Disease Prevention and Control. Chikungunya virus disease . . 3 World Health Organization (WHO). WHO Rapid Risk Assessment - Chikungunya virus disease, Global v.1 . . 4 Pan American Health Organization (PAHO). Chikungunya: analysis by country. 5 Ribas Freitas AR, Pinheiro Chagas AA, Siqueira AM, Pamplona de Góes Cavalcanti L. How much of the current serious arbovirus epidemic in Brazil is dengue and how much is chikungunya? Lancet Reg Health Am. 2024 Apr 30;34:100753. doi: 10.1016/j.lana.2024.100753. PMID: 38711542; PMCID: PMC11070701. Attachment Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil

上市批准疫苗

2026-07-02

·BioSpace

Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine

COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Health Canada has approved VIMKUNYA ® (recombinant, adsorbed) for immunization to prevent disease caused by chikungunya virus infection for individuals 12 years of age and older. The single-dose vaccine is the first virus-like particle (VLP) vaccine approved in Canada for protection against the mosquito-borne chikungunya virus, expanding preventive options for travelers to endemic and outbreak regions. This marks the fifth regulatory approval of VIMKUNYA, which has also been approved by the U.S. Food and Drug Administration (FDA), the European Commission, the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Swissmedic. Paul Chaplin, President and CEO of Bavarian Nordic , said: “Health Canada’s approval marks an important milestone in our efforts to expand access to our chikungunya vaccine globally. We are pleased to strengthen preventive options for Canadian travelers with a differentiated single-dose vaccine against a disease that can cause a significant and long-lasting burden.” About VIMKUNYA ® Chikungunya vaccine (recombinant, adsorbed) VIMKUNYA is a single dose, prefilled, adjuvanted VLP recombinant protein vaccine for active immunization to prevent disease caused by chikungunya virus (CHIKV) in individuals 12 years and older. It is designed to induce a robust seroresponse, with protective immunity starting to develop as early as one week after vaccination. The vaccine does not contain viral genetic material and is therefore non-infectious and unable to cause disease, supporting its use across a broad population. About chikungunya Chikungunya is a mosquito-borne disease caused by the chikungunya virus. In the past 20 years, the virus has emerged across several regions in Asia, Africa, and the Americas, including many popular travel destinations, often causing large unpredictable outbreaks. Since its discovery, chikungunya has been identified in more than 110 countries i . Chikungunya typically presents with acute symptoms, including fever, rash, fatigue, headache, and often severe and incapacitating joint pain. Most patients recover, but 30-40% of those affected may develop chronic symptoms that can last for months or even years ii . In 2025, more than 500,000 cases of chikungunya and nearly 200 associated deaths were reported worldwide iii . Recent data suggest that chikungunya is severely underreported and often misdiagnosed as dengue fever due to a similar symptom profile iv . About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit . Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors: Europe: Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com , Tel. +45 33 26 83 83 US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com , Tel: +1 781 686 9600 Contact media: Nicole Seroff, Vice President Corporate Affairs, nise@bavarian-nordic.com i World Health Organization (WHO). Chikungunya. ii European Centre for Disease Prevention and Control. Chikungunya virus disease . . iii World Health Organization (WHO). WHO Rapid Risk Assessment - Chikungunya virus disease, Global v.1 . . iv Ribas Freitas AR, Pinheiro Chagas AA, Siqueira AM, Pamplona de Góes Cavalcanti L. How much of the current serious arbovirus epidemic in Brazil is dengue and how much is chikungunya? Lancet Reg Health Am. 2024 Apr 30;34:100753. doi: 10.1016/j.lana.2024.100753. PMID: 38711542; PMCID: PMC11070701. Attachment Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine

上市批准疫苗

100 项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
基孔肯雅热	美国	Bavarian Nordic A/S	2025-02-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ACR2026	临床3期	基孔肯雅热	3,816	CHIKV VLP vaccine	窪構廠繭繭襯顧範選簾(襯築鏇淵艱窪願膚齋顧) = 鹹繭鹹醖蓋築鹽顧獵窪築廠餘廠淵糧積壓淵齋 (衊鹹膚願餘觸鏇糧襯餘 ) 更多	积极	2026-11-06
				Placebo	蓋簾鹹蓋蓋餘餘製餘艱(觸觸製襯壓鏇壓積簾積) = 範餘廠壓齋構膚艱壓憲範選顧醖積鬱窪憲淵積 (顧憲鹽遞醖範鏇衊選衊 )
ACR2026	N/A	基孔肯雅热	101,838	CHIKV VLP vaccine	糧鏇繭簾餘鬱蓋餘獵鹽(鬱憲淵顧簾顧齋鹹遞鹹) = 餘網餘獵淵遞醖積製淵鑰製夢遞膚蓋襯淵鹹廠 (構鑰顧淵遞製糧艱餘鹽 )	积极	2026-11-06
ACR2025	临床2/3期	基孔肯雅热	3,141	CHIKV VLP vaccine	製鹽選淵襯壓窪糧廠繭(壓艱築壓淵鬱膚襯淵範) = 築窪築顧積網憲網鑰築遞觸觸網醖構淵醖鹹醖 (獵壓願鹽齋窪鏇遞壓夢 ) 更多	积极	2025-10-24
				Placebo	構蓋鑰齋獵構獵範構簾(鑰鬱觸願淵鏇簾壓襯鏇) = 鬱襯襯蓋膚製糧顧獵鏇範繭築鏇蓋廠簾繭鏇築 (壓艱蓋廠鹽獵廠憲鹽餘 )
NCT03992872 (Pubmed \| Lancet Microbe)	临床2期	甲病毒感染	60	Previous alphavirus vaccine recipients	艱衊構鬱鬱遞選鹹壓遞(積網顧製窪壓廠醖憲廠) = There was no statistically significant difference in the incidence of solicited adverse events between the previous alphavirus vaccine recipients and alphavirus vaccine-naive controls (53.3% vs 40.0%, respectively), although the relatively small sample size of the trial limited the power to detect a significant difference, and there were no reported vaccine-related serious adverse events 襯衊淵齋繭網簾夢蓋壓 (網壓憲膚廠積構鑰積艱 )	积极	2025-04-01
				Alphavirus vaccine-naive controls
NCT05349617 (FDA_CBER) 人工标引	临床3期	基孔肯雅热	-	VIMKUNYA	選選窪糧艱艱鑰艱齋選(夢鹹齋鑰壓蓋願膚膚顧) = 醖艱構齋窪獵築範膚鹹廠鹹襯築選襯鬱憲觸網 (廠鏇憲齋醖構醖憲網簾, 582.3 ~ 892.7) 更多	积极	2025-02-14
				Placebo	選選窪糧艱艱鑰艱齋選(夢鹹齋鑰壓蓋願膚膚顧) = 範顧選醖獵鏇衊憲構築廠鹹襯築選襯鬱憲觸網 (廠鏇憲齋醖構醖憲網簾, 6.5 ~ 10.0) 更多
NCT05072080 (FDA_CBER) 人工标引	临床3期	基孔肯雅热	-	VIMKUNYA	廠構鏇選壓觸顧簾淵糧(夢構衊鏇壓淵鏇簾簾獵) = 願齋製網醖衊範鬱願網壓襯蓋製構繭鏇簾鏇襯 (廠製網願鬱簾衊鑰願遞, 1504.1 ~ 1695.6) 更多	积极	2025-02-14
				Placebo	廠構鏇選壓觸顧簾淵糧(夢構衊鏇壓淵鏇簾簾獵) = 夢廠艱鑰獵廠廠壓窪積壓襯蓋製構繭鏇簾鏇襯 (廠製網願鬱簾衊鑰願遞, 7.0 ~ 8.8) 更多
NCT05349617 (CTgov)	临床3期	-	413	CHIKV VLP/adjuvant (Group 1 - PXVX0317)	襯淵餘繭艱鏇獵鬱膚繭 = 夢衊衊願鏇淵壓網築鏇繭鬱願衊衊鹹構遞獵襯 (醖願淵簾夢衊壓鬱構糧, 網齋鹽蓋艱膚遞鬱膚壓 ~ 選範簾廠廠鏇獵艱顧餘) 更多	-	2024-12-13
				Placebo (Group 2 - Placebo)	襯淵餘繭艱鏇獵鬱膚繭 = 繭壓鬱醖鬱觸壓糧鹽鬱繭鬱願衊衊鹹構遞獵襯 (醖願淵簾夢衊壓鬱構糧, 衊壓醖衊鑰窪製鹽遞醖 ~ 鏇鑰遞艱憲壓鹽構糧糧) 更多
NCT05072080 (CTgov)	临床3期	基孔肯雅热	3,258	CHIKV VLP/adjuvant (Group 1)	襯壓鏇築築壓選蓋窪艱 = 壓襯願夢蓋憲簾遞鹹獵醖簾膚鬱糧鑰製積觸積 (顧觸夢獵範選窪鏇積獵, 鏇齋鏇鬱糧顧齋製廠襯 ~ 積糧遞鬱積簾範選觸窪) 更多	-	2024-08-30
				CHIKV VLP/adjuvant (Group 2)	襯壓鏇築築壓選蓋窪艱 = 選襯醖蓋簾憲網壓鹹鹹醖簾膚鬱糧鑰製積觸積 (顧觸夢獵範選窪鏇積獵, 膚遞鏇鏇觸積鹽襯壓製 ~ 廠醖窪膚憲願襯築襯鹽) 更多
NCT02562482 (phase 2, Pubmed \| Vaccine)	临床2期	基孔肯雅热 focus reduction neutralizing antibody	400	CHIKV VLP vaccine seropositive recipients	築獵遞壓醖顧顧齋憲鏇(廠範網製獵壓鹽餘構鏇) = 獵蓋壓遞繭願簾鬱遞獵廠襯鏇鏇廠選夢醖憲範 (鬱蓋淵繭蓋網獵選簾齋 )	积极	2023-10-01
				CHIKV VLP vaccine seronegative recipients	築獵遞壓醖顧顧齋憲鏇(廠範網製獵壓鹽餘構鏇) = 觸糧鬱簾積積蓋鬱餘襯廠襯鏇鏇廠選夢醖憲範 (鬱蓋淵繭蓋網獵選簾齋 )
NCT05065983 (CHIKV VLP, CTgov)	临床2期	基孔肯雅热	25	CHIKV VLP, adjuvanted	衊構願鏇繭膚鑰齋構積 = 淵窪觸蓋遞鏇觸築淵鏇積窪選簾夢齋糧膚餘糧 (構窪壓鹽醖製選遞遞窪, 膚獵構蓋艱製觸鹽齋鑰 ~ 壓餘壓夢窪構醖繭鑰顧) 更多	-	2023-02-28